Emerging evidence indicates that suppression of protein kinase C (PKC) renders the susceptibility of cells expressing mutated ras to apoptosis. Although the effort has been made, the underlying molecular mechanisms are not fully understood. In this study, using small hairpin RNAs (shRNAs) or PKC inhibitor, we show that the concurrent suppression of PKC-a and b induces cells ectopically expressing v-ras to undergo apoptosis. In this apoptotic process, PKC-d is upregulated and translocated from the cytosol to the nucleus. The activated PKC-d associates with and phosphorylates p73 to initiate apoptosis. In this apoptotic process, Akt seems to be downstream of oncogenic Ras. Moreover, overexpression of PKC-d, without co-suppression of PKC-a and b, is not apoptotic to the cells, suggesting that PKC-d and PKC-a/b function oppositely to facilitate cells harboring v-ras to survive. Thus, our study shows that PKC-a and b are necessary for sustaining the homeostasis in cells containing a hyperactive Ras. The abrogation of these two isoforms switches on the p73-regulated apoptotic machinery through the activation of PKC-d.
Introduction
Protein kinase C (PKC), a family of serine/threonine protein kinases, consists of more than 10 isoforms that differ in their structures, cellular functions and tissue distributions (Nishizuka, 1995; Gutcher et al., 2003; Spitaler and Cantrell, 2004) . PKC a, b I , b II and g are categorized as the conventional or classic PKC isoforms that are dependent on calcium and diacylglycerol for the activation, whereas isozymes of unconventional PKC subgroup (PKC d, e, Z and y) are independent of calcium for their functions. The atypical PKC isozymes (PKC z and l/n) require neither diacylglycerol nor calcium for being activated. The structural diversity and different tissue distributions render distinct specificities of PKC isozymes that differentially regulate various cellular signaling pathways and further dictate different biological outcomes, including apoptosis. Recently, with the availability of small hairpin RNA (shRNA) and other genetic means to disrupt individual PKC isoform in vitro and in vivo, studies showed that PKC isoforms are either pro-or anti-apoptotic, depending upon cell types, stimuli or contexts within signaling pathways (Matassa et al., 2001; Brodie and Blumberg, 2003; Gutcher et al., 2003; Reyland, 2007) .
The Ras family consists of a group of small GTPases (including three major members: Ha-, Ki and N-Ras) that, through governing various downstream effectors, regulate diverse cellular biological processes, including proliferation, differentiation, motility, transformation and apoptosis. In approximately 30% of human malignancies, Ras proteins are mutated. The active, guanosine-5'-triphosphate (GTP)-bound form of Ras interacts with its downstream effectors and stimulates their activities. The balance among different intracellular signaling pathways is a key element to determine the fate of cells. Under conditions of stresses (such as downregulation of endogenous PKC activity, loss of matrix adhesion or tamoxifen treatment), active Ras in lymphocytes or fibroblasts promoted apoptosis (Chen et al., 1998a) . Apoptosis initiated by mutated Ras seemed to involve multiple downstream signaling pathways (Chen et al., 1998b) . The effort to determine the downstream effectors of Ras in transmitting proapoptotic signaling has been made. For example, overexpression of Raf renders mouse fibroblasts the susceptibility to apoptosis (Wang and Reed, 1998) . Sustained activation of mitogen-activated protein kinase pathway in Swiss3T3 cells was linked to the induction of apoptosis (Fukasawa et al., 1995) . Oncogenic Ras was also shown to use c-Jun N-terminal kinase (JNK) and phosphatidylinositol-3-kinase (PI3K)/Akt pathways to execute cell death program (Chen et al., 2001; Guo et al., 2009) . Recently, using large-scale RNA interference screens, the kinase-dependent vulnerabilities of cancers harboring oncogenic K-ras was shown Scholl et al., 2009) .
Protein kinase C-d is a multifunctional kinase that is expressed in various tissues. Using the knockout mouse model, studies showed that PKC-d has an important role in controlling diverse cell activities, including cell proliferation (Li et al., 1998; Kiley et al., 1999; Braun and Mochly-Rosen, 2003; Jackson and Foster, 2004) , immune responses, migration and apoptosis (Li et al., 1998; Eitel et al., 2003; Brodie and Blumberg, 2003; Kajimoto et al., 2004; Murriel et al., 2004; Atten et al., 2005; Zhang et al., 2005; Kheifets et al., 2006) . However, the role of PKC-d in the regulation of apoptosis is rather controversial. This isoform of PKC was shown to be required for insulin-like growth factor-I receptormediated transformation (Li et al., 1998) . Inhibition of PKC-d was shown to sensitize several v-Ki-expressing or Ha-ras expressing cells to apoptosis (Xia et al., 2007) . However, other studies showed that this serine/threonine kinase is a critical pro-apoptotic factor in apoptosis induced by different apoptotic stimuli. For example, PKC-d confers the susceptibility of human glioma or myeloma cells to apoptosis induced by anticancer drugs (Mandil et al., 2001; Ni et al., 2003) . The activation of this PKC isoform was also required for cell death induced by ultraviolet irradiation, genotoxins, brefeldin A and death receptor (Emoto et al., 1995 Mizuno et al., 1997; Reyland et al., 1999; Matassa et al., 2001) . Moreover, it was reported that although PKC-d-null mice are not susceptible to cancer, the numbers of smooth muscle cells in the mice are increased, and they are resistant to genotoxins and other apoptotic stimuli (Humphries et al., 2006) .
Upon apoptotic stimulation, PKC-d was activated and subsequently translocated to the nucleus (Emoto et al., 1995 Kaul et al., 2005) . Ectopic expression of the active PKC-d alone was sufficient to trigger apoptosis, even under the condition lacking apoptotic stimulation. In the process, PKC-d was associated with apoptotic factors, such as Bax, and further activated them for the induction of apoptosis (Denning et al., 1996; Sitailo et al., 2004) . Loss of functional mutations of PKC-d blocks its nuclear translocation as well as its ability to induce apoptosis (Ghayur et al., 1996; DeVries-Seimon et al., 2007) . In particular, the introduction of a kinase-dead PKC-a mutant caused salivary epithelial cells to undergo apoptosis in a PKC-ddependent manner (Matassa et al., 2001) . In this apoptotic process, JNK was activated, accompanied by an increase in caspase 3 activity. p53 exerts its tumor suppression function through controlling cell-cycle checkpoints and regulating apoptosis (Levine, 1997) . p73 and p63 belong to the p53 family and share homology with p53 in not only their sequence but also their transactivation, DNA binding and oligomerization functions. These two p53-related molecules have been shown to be able to activate p53-responsive genes in a p53-independent manner. Studies also showed that p73 is involved in the cellular response to DNA damage or genotoxic stress (Jost et al., 1997; Yang et al., 2002) . For example, in response to DNA damage, the activated PKC-d was able to bind to and phosphorylate p73, leading to apoptosis (Ren et al., 2002) .
In this study, the experiments showed that mutated Ras, together with concurrent suppression of PKC-a and b, were apoptotic. In this apoptotic process, PKC-d was upregulated and translocated to the nucleus. The active PKC-d then interacted with and activated p73 for the induction of apoptosis. However, overexpression of PKC-d without suppression of PKC-a/b is not lethal, suggesting that PKC-d and PKC-a/b might function oppositely to maintain homeostasis in the cellular environment controlled by hyperactive Ras.
Results
Concurrent suppression of protein kinase C (PKC)-a and b induces apoptosis in the cells with aberrant Ras signaling The addition of GO6976 (a potential PKC-a and b inhibitor) induced various types of cells expressing an active ras to undergo apoptosis (Guo et al., 2009) . The suppression of PKC-a by a kinase-dead PKCa mutant was also reported to render salivary epithelial cells the susceptibility to undergo PKC-d-dependent apoptosis (Matassa et al., 2001) . As GO6976 was shown to affect the activity of other types of serine/threonine kinases (for example, Chk1; Aaltonen et al., 2007) to identify which PKC isozymes are necessary for the induction of apoptosis, the shRNAs against PKC-a and b were used. Murine NIH3T3 cells were first stably infected with v-Ha-ras (designated as NIH3T3/Hras) and the expression of Ras was tested afterward using immunoblotting ( Figure 1a , left panels). NIH3T3/Hras cells expressed an increased amount of Ras and the relative expression of the protein to the control was determined using densitometry. The activation status of Ras was also measured using the Active Ras Pull-Down and Detection kit (Thermo Scientific, Rockford, IL, USA), in which increased GTP-bound Ras was only detected in NIH3T3/Hras cells, but not in the parental cells ( Figure 1a , right panels). For confirmation purpose, the induction of apoptosis by GO6976 in these cells was examined using DNA fragmentation (Figure 1b, left panel) and Annexin V-fluorescein isothiocyanate (FITC) apoptotic detection (Figure 1b , right panel) assays. Consistently, after being treated with the inhibitor for 48 h, >30% of the NIH3T3/Hras cells underwent apoptosis, and very low numbers of the parental cells were apoptotic. The data indicate that GO6976 is able to induce apoptosis, and that PKC-a and b might be the potential targets for sensitizing cells expressing v-ras to apoptosis.
To determine whether suppression of PKC-a and b is necessary for the initiation of apoptosis, the shRNAs targeting PKC-a, b and corresponding scrambled shRNAs were transiently infected into the cells. The knockdown of the expression of these two PKC isoforms by the shRNAs was examined using immunoblotting ( Figure 2a , left panels). The level of PKC-a was dramatically knocked down by the shRNA, but not by shRNA-PKC-b or scrambled shRNA. The similar phenomenon was observed in the knockdown of PKCb. The relative expression levels of PKC-a and b were measured ( Figure 2b, right panel) . Subsequently, the induction of apoptosis, after the suppression of PKC-a, b or both by the shRNAs, was tested using DNA fragmentation assay (Figure 2b, left panel) . The knockdown of PKC-a or b alone by each shRNA had no role in the induction of apoptosis in the cells with or without expressing v-Ha-ras. However, the concurrent knockdown of these two PKC isozymes caused approximately 50% of NIH3T3/Hras cells to undergo apoptosis. A similar result was obtained from Annexin V-FITC apoptosis detection assay (Figure 2b , right panel). The shRNAs targeting other phorbol esterdependent PKC e, y or Z were also used and none of them, alone or in various combinations, was able to sensitize the cells to apoptosis (data not shown). Thus, PKC-a and b are the targets for the induction of apoptosis in NIH3T3/Hras cells.
It was reported that the treatment with GO6976 induced cells expressing v-ras or tumor cells harboring an active ras to apoptosis, in which Akt functioned as Ras downstream, apoptotic effector (Guo et al., 2009) . To test whether Akt participated in apoptosis triggered by loss of PKC-a and b, human prostate cancer PC3 cells that are known to contain the active form of Akt and HPV7 cells were used. The levels of Akt phosphorylated at Ser-308 and 473 were examined using the anti-phophorylated Akt antibodies (Figure 2c) . A high level of phosphorylated Akt at either Ser-308 or 473 was detected in PC3 cells. The active forms of Akt in HPV7 were at a very low level. The knockdown effect of PKCa or b by the shRNAs in these prostate cancer cells was then tested (Figure 2d ). The shRNAs effectively blocked the expression of corresponding proteins, and did not show any off-target effect on the unrelated PKC isoforms. Annexin V apoptotic analysis was used to 
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(a mitogen-activated protein kinase/extracellular signalregulated kinase inhibitor), blocked this apoptotic process. Next, murine lung epithelial LA4 and cancer LKR cells harboring a mutated ras were tested for their susceptibility to apoptosis after co-knockdown of PKCa and b (Figure 2f ). Consistently, concurrent inhibition of these two PKC isoforms induced LKR cells (approximately 40%) to undergo apoptosis, and had no role in control LA4 cells. PC3 cells seemed to be less sensitive to the knockdown of PKC-a and b than LKR cells, which may be because other Ras downstream pathway(s), besides Akt, participate in this apoptotic process, or because of differences in cell types.
Activation of protein kinase C (PKC)-d in NIH3T3/Hras cells after concurrent suppression of PKC-a and b
Protein kinase C-d often functions as a tumor suppressor by either inducing growth arrest or by activating pro-apoptotic signals in many types of cells (Brodie and Blumberg, 2003; Gutcher et al., 2003) . The suppression of this isoform was linked to apoptosis in cells expressing oncogenic ras (Xia et al., 2007) . In this study, we tested whether PKC-d had any role in this apoptotic process. The expression of PKC-d in NIH3T3/ Hras cells was examined using immunoblotting after concurrently knocking down PKC-a and b by the shRNAs or GO6976 (Figure 3a) . After co-suppressing PKC-a and b, the level of PKC-d was upregulated in NIH3T3/Hras, but not in parental cells. The activity of PKC-d, after co-suppression of PKC-a and b, was also measured (Figure 3b ). After the cells were infected with shRNAs or treated with GO6976, cell lysates were , 2007) . The subcellular localization of this isozyme in our experimental setting was tested. After being co-infected with shRNA-PKC-a and b (Figure 4a ) or GO6976 treatment (Figure 4b ), the cytosol and nuclear fractions were isolated from NIH3T3 and NIH3T3/Hras cells and immunoblotted with anti-PKC-d antibody. In NIH3T3 cells, a moderate amount of PKC-d was detected in the cytosol fractions with or without the treatments, and the protein was almost undetectable in the nuclear fractions. In contrast, a high amount of this isoform was present in the nuclear fractions of NIH3T3/ Hras cells after co-suppression of PKC-a and b or the treatment with GO6976. The data indicated that PKC-d was activated and translocated to the nucleus upon co-suppression of PKC-a and b.
To further confirm the nuclear translocation of PKC-d, NIH3T3/Hras cells were co-infected with shRNA-PKC-a and b and then subjected to immunohisto- 
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T Zhu et al chemistry analysis using anti-PKC-d antibody as the primary antibody and goat anti-mouse immunoglobulin antibody conjugated with fluorescein as the secondary antibody. The fluorescent staining was mainly observed in the cytosol of untreated cells. In contrast, after coknockdown of PKC-a and b, fluorescein-stained protein appeared in the nucleus, which was overlapped with 4 0 ,6-diamidino-2-phenylindole-stained nuclei. The similar phenomenon was obtained from the cells treated with GO6976 (data not shown). To further confirm that the nuclear translocation is specific to PKC-d, after being co-infected with shRNA-PKC-a and b, NIH3T3/ Hras cells were stained with anti-PKC y (Figure 4d ), e ( Figure 4e ) and Z (Figure 4f ) antibodies, respectively, and then the secondary fluorescein-conjugated antibody. None of these PKC isoforms was detected in nucleus upon the knockdown of PKC-a and b. These results further suggest the nuclear translocation of PKC-d in the cells expressing v-ras under the apoptotic condition.
p73 is phosphorylated and interacted with protein kinase C (PKC)-d during the apoptotic process p73 is a member of p53 tumor suppressor family and involved in the regulation of apoptosis upon genotoxic stress or after exposure to apoptotic stimuli (Whelan and Parker, 1998; Agami et al., 1999; Gong et al., 1999; Costanzo et al., 2002; Gonzalez et al., 2003; Irwin et al., 2003) . Studies showed that PKC-d could induce different types of cells to undergo apoptosis in response to DNA damage, in which p73 was activated (Ren et al., 2002; Reyland, 2007) . As PKC-d is activated in our experimental setting, cell lysates from the cells with or without the co-knockdown of PKC-a and b were prepared and the expression of p73 was analysed using immunoblotting ( Figure 5a ). An increased amount of p73 was detected by the antibody in the lysate from NIH3T3/Hras cells after the co-infection of shRNA-PKC-a and b, but not from parental cells. Subsequently, the nuclear association of PKC-d and p73 was analysed. To exclude the existence of other PKC isoforms in the immunoprecipitates, the complexes pulled out by anti-PKC-d antibody were immunoblotted with anti-PKC e, Z or y antibody, and none of these isoforms was being detected (Figure 5b , third, fourth and fifth rows). The immunoprecipitation with anti-PKC e, Z or y antibody and subsequent immunoblotting with anti-p73 antibody were also performed. There were no interactions between p73 and these isoforms with or without knockdown of PKC-a and b (data not shown). Next, the reciprocal co-immunoprecipitation and immunoblotting were performed (Figure 5c ). A similar result was obtained, in which the complexes precipitated with anti-p73 antibody from treated NIH3T3/Hras cells were recognized by anti-PKC d antibody. Activated PKC-d is implicated to phosphorylate p73 at serine/threonine residues during apoptosis (Ren et al., 2002; Gonzalez et al., 2003) . As PKC-d physically associated with p73 after the co-suppression of PKC-a and b, we then tested whether p73 was phosphorylated under the apoptotic condition. After being co-infected with shRNA-PKC-a and b , the cells were subjected to immunoprecipitation with anti-p73 antibody and then to immunoblotting with the anti-phosphoserine antibody (Figure 6a ). The phosphorylated p73 was detected in only NIH3T3/Hras cells after knockdown of PKC-a and b, but not in parental cells. To further evaluate the necessity of p73 for the initiation of this apoptotic process, the shRNA targeting p73 was introduced into NIH3T3/Hras cells after concurrently suppressing PKCa and b. The effect of the triple knockdown of p73, PKC-a and b was analysed using immunoblotting ( Figure 6b ). The shRNAs sufficiently inhibited the expression of these molecules. Subsequently, the occurrence of apoptosis was assayed using Annexin V-FITC method (Figure 6c ). The suppression of p73 partially blocked the apoptotic process in NIH3T3/Hras cells, indicating that p73 has a role in the induction of this cell death process. However, the incomplete suppression of the apoptotic process by shRNAp73 suggests the involvement of other apoptotic factors or the partial inhibition of p73, PKC-a or b by the shRNAs.
Cooperation among protein kinase C (PKC) isoforms for the induction of apoptosis
To further define the role of PKC-d in the induction of the apoptotic signaling transmitted by aberrant Ras, wild-type PKC-d (WT-PKCd) or the constitutively active form of PKC-d (CAT-PKCd) was transiently transfected into NIH3T3/Hras cells, and the expression of exogenous WT-PKCd and CAT-PKCdwas determined using immunoblotting (Figure 7a ). Different forms of exogenous PKC-d were overexpressed in the cells. The occurrence of apoptosis with or without the concurrent knockdown of PKC-a and b was then analysed using Annexin V-FITC assay (Figure 7b) . Interestingly, the overexpression of either WT-PKCd or CAT-PKCd alone was unable to induce apoptosis in NIH3T3/Hras cells. After co-inhibition of PKC-a and b, the increased expression of PKC-d or CAT-PKCd not only induced apoptosis but also enhanced the magnitude of apoptosis in the cells. The same phenomenon was also observed in murine lung cancer LKR cells overexpressing WT-PKCd or CAT-PKCd (data not shown). Overall, the results suggest that the pro-apoptotic activity of PKC-d is elicited only when PKC-a and b are concurrently suppressed.
Discussion
The study of Ras oncogene is a popular theme in the field of cancer research in light of the pivotal roles Apoptosis regulated by PKCs and mutated Ras T Zhu et al of Ras in the regulation of diverse cellular activities, such as proliferation, differentiation, senescence and apoptosis. In the process of tumorigenesis, it is critical for hyperactive Ras to maintain the balance in deregulated downstream effectors and to properly coordinate with other intracellular signals. Disruption of one or more of these signaling pathways would perturb homeostasis in cells harboring a mutated Ras and further trigger an apoptotic crisis. Recently, genome-wide RNA interference screens reveal that suppression of kinases involved in the regulation of cell growth is synthetic lethal with oncogenic K-ras Scholl et al., 2009) . Such synthetic lethal interaction also occurs between Hor K-Ras and loss of PKC (Chen et al., 1998a, b; Xia et al., 2007) . In this study, using shRNAs, we identified PKC isoforms critical for supporting the viability of cells expressing oncogenic ras. We showed that after the concurrent suppression of PKC-a and b, PKC-d in the cells expressing an aberrant Ras was upregulated and further translocated from the cytosol to the nucleus in which it phosphorylated p73 for the induction of apoptosis. This PKC-d-mediated apoptotic signaling was activated only under the condition when PKC-a and b were concurrently suppressed. Thus, our study not only indicates that mutated Ras, together with loss of PKC-a and b, is apoptotic, but also suggests a potential balance among PKC isoforms in the regulation of the susceptibility of cells expressing v-ras to apoptosis. Mutational activation of ras genes is a key event in human cancer development. During transformation process, cells develop secondary, adaptive mechanisms to cope with persistently increased Ras activity (Barbacid, 1987; Lowy and Willumsen, 1993; McCormick, 1993) . Survival of these cancer cells depend on factors that are downstream or parallel to Ras signaling pathway, or distal to Ras but functionally linked. Changes in the expression or activity of these factors would trigger a lethal consequence. The possibility of synthetic lethal interaction of oncogenic Ras with various cell growth regulators has been discussed (McNeill and Downward, 1999) . The study, exclusively using rottlerin, showed that the inhibition of PKC-d sensitizes various ras-transformed cells (including NIH3T3 cells expressing v-Ha-ras) or tumor cells to apoptosis (Xia et al., 2007) . In this process, Akt seemed to be crucial for the apoptotic action. It was also reported that the suppression of PKC-a by the kinasedead mutant gene elicited PKC-d/z-dependent apoptosis in salivary epithelial cells, accompanied with JNK activation (Matassa et al., 2001) . Previously, using genetic and chemical inhibitors, we showed that PI3K/ Akt and JNK are involved in the induction of a full magnitude of apoptosis in response to PKC suppression (Guo et al., 2009) . In this study, using prostate cancer PC3 cells, it seems that after the co-knockdown of PKCa and b, Akt functions as one of Ras downstream, apoptotic effectors. The differential activations of Ras downstream effector pathways in each experimental setting may reflect the consequences of the different strategies used to suppress PKC or different types of cells used. Protein kinase C isoforms are serine/threonine protein kinases that are structurally distinct and functionally diverse. There is functional redundancy among PKC isozymes for restoring normal physiological status when one or more PKC isozymes are disabled. The functions of PKC isoforms have been shown to be rather controversial, which often depend on different cellular contexts or types of stimuli. For example, studies showed that PKC-a, b, d, e or z could either positively or negatively regulate tumorigenesis and apoptosis, indicating the functional complexity of PKC isozymes (Gutcher et al., 2003; Spitaler and Cantrell, 2004) . Studies have also shown the interconnection between PKC and Ras signaling pathways (Kampfer et al., 2001; Rusanescu et al., 2001) . Upon mitogenic stimulation, the Src homology 2 binding sites of PKC are phosphorylated, which in turn recruit Grb2/SOS complex and activate Ras pathway in T lymphocytes (Kawakami et al., 2003) . PKC is also indicated in the negative regulation of Ras signaling through modulating Ral activity (Rusanescu et al., 2001) . The inhibition of PKC-a was able to induce apoptosis through eliciting oxidative or endoplasmic reticulum stress in cells (Reyland, 2007) . We previously showed that the suppression of PKC by GO6976 (a potential PKC-a and b inhibitor) triggers apoptosis through Aktmediated endoplasmic reticulum stress (Guo et al., 2009) . GO6976 was shown to affect the activity of other types of serine/threonine kinases (for example, Chk1) (Aaltonen et al., 2007) . The present study, using shRNAs to specifically co-knockdown PKC-a and b, confirms the roles of these two PKC isoforms to induce cells expressing aberrant H-ras to undergo apoptosis, in which PKC-d is activated. It is conceivable that oncogenic H-Ras, through PI3K/Akt, influences PKCd activity for the induction of apoptosis.
Protein kinase C-a and b have been traditionally referred to as promoting survival in different types of cells, such as endothelial, glioma and epithelial cells (Li et al., 1998; Whelan and Parker, 1998; Deng et al., 2001) , whereas PKC-d has been shown to be a tumor suppressor (Emoto et al., 1995) . Under certain circumstances (such as different types of cells), PKC-d was shown to promote cell proliferation (Jackson and Foster, 2004) . Our study showed that in cells expressing oncogenic ras, overexpression of WT-PKCd or CATPKCd alone is not apoptotic. However, once concurrently knocking down PKC-a and b, the d isozyme is upregulated, and becomes lethal for the cells. It is possible that a balance that is controlled by PKC-a/b and d copes with hyper-active Ras. Once this balance is disrupted, an apoptotic catastrophe occurs. Or, it is conceivable that cross-talks among PKC isoforms or with other intracellular signal transducers (such as Ras) exist in a hierarchic or parallel order within different subcellular compartments, which guide cells to achieve various biological outcomes.
Protein kinase C-d is activated by various apoptotic stimuli (such as ultraviolet radiation, g-irradiation and genotoxic agents) in a variety of cell lines (for example, HeLa and HL60 cells; Reyland, 2007) . A direct regulation of the expression of PKC-d by activated Ras or PI3K under normal growth conditions was suggested (Xia et al., 2007) . In salivary epithelial cells, the blockade of PKC-a by a dominant-negative PKC-a triggered PKC-d-dependent apoptosis, in which extracellular signal-regulated kinase was upregulated (Matassa et al., 2003) . It was shown that in doxorubicininduced apoptosis, JNK, through activating c-Jun and ATF2 transcription factors, is responsible for an increasing expression of PKC-d gene (Min et al., 2008) . In our experimental setting, Akt seems to take part in the apoptotic process upon the co-suppression of PKC-a and b. It is conceivable that Akt, as a downstream of oncogenic Ras, affects the activity of transcription factors and further PKC-d expression, the mechanisms of which is under way to be analysed. p73 is a structural and functional homolog of p53, and participates in apoptosis initiated by DNA damage stimuli. Studies showed that nuclear c-Abl was involved in p73-mediated apoptosis induced by genotoxic agents (Walworth et al., 1993; Agami et al., 1999) . In this process, the nuclear c-Abl interacts with p73 and stimulates p73-regulated signaling. It is also known that in response to ionizing radiation or to cisplatin treatment, p73 functions as a key element in apoptosis triggered by PKC-d (Ren et al., 2002) . The present study shows that PKC-d translocated from the cytosol to the nucleus and activated p73 there during the apoptotic process. However, the inhibition of p73 partially blocked the process of cell death. Thus, our finding does not exclude the possibility that other factors, besides PKC-d, are involved in p73 activation in the current experimental setting. It is also likely that the partial suppression of apoptosis is due to incomplete suppression of p73.
As >30% of human malignancies contain Ras mutations, targeting oncogenic Ras is viewed as an important strategy for development of new anticancer therapies. In this study, we show that the concurrent suppression of PKC-a and b induces the cells ectopically expressing v-ras or cells with aberrant Akt signaling to undergo apoptosis, suggesting that hyperactive Ras and PI3K/Akt have essential roles in this apoptotic pathway. Ras and PKC are important intracellular signal transducers for cell differentiation and proliferation. Dyregulation of Ras or PKC alone is compatible with cell viability. However, our current study suggests that aberrant Ras signaling, together with loss of PKC-a and b, severely perturb crucial survival signaling and further elicit an apoptotic crisis in the cell. With increasing attention in targeting Ras signaling for cancer treatment, our study provides the evidence for developing new therapeutic strategies to preferentially kill tumor cells harboring an active ras at clinically achievable doses, with effective indices that are higher than those of classic cytotoxic drugs.
Materials and methods

Cells and reagents
Murine fibroblasts NIH3T3 and lung epithelial LA4 cells were purchased from ATCC (Manassas, VA, USA). Murine lung cancer LKR cells that isolated from lung foci of v-ras transgenic mouse were obtained from Dr Yu (Boston University). Human prostate cancer HPV7 and PC3 cells were provided by Dr Luo (Boston University). These cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA, USA), 100 units/ml penicillin, 100 mg/ml Streptomycin (Invitrogen, Rockville, MD, USA), except that LA4 cells were kept in Ham's F12K medium supplemented with 15% fetal bovine serum. GO6976, JNK inhibitor and PD98059 were purchased from EMD (Gibbstown, NJ, USA) and KP372-1 was from Echelon Biosciences Inc. (Salt Lake City, UT, USA). Antibodies against PKC-a, b and Ras were purchased from BD Biosciences (San Jose, CA, USA) and those against PKC-d and p73 were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The anti-phosphotyrosine or anti-phosphoserine antibodies were obtained from Millipore (Billerica, MA, USA) and Sigma (St Louis, MO, USA), respectively. The antibodies against Akt or active Akt were purchased from Cell Signaling Inc. (Danvers, MA, USA).
The oligonucleotides containing small interference RNA sequences targeting different protein kinase C isozymes were ligated to a lentiviral shRNA expression vector pLentiLox3.7. The sequences of the small interference siRNAs are: 5 0 -GAA CGTGCATGAGGTGAAA-3 0 and 5 0 -TCTGCTGCTTTGTT GTACA-3 0 for murine PKC-a and PKC-b, 5 0 -GGCTGTAC TTCGTCATGGA-3 0 and 5 0 -CAGGAAGTCATCAGGAA TA-3 0 for human PKC-a and PKC-b. The small interference RNA sequence for p73 is as reported (Chau et al., 2004) . The plasmids expressing WT-PKCd and CAT-PKCd were generously gifted by Dr J Soh (Inha University, South Korea). v-Ha-ras was inserted into a retroviral murine stem cell virus vector (Clontech Laboratories, Mountain View, CA, USA). FuGene 6 transfection reagent (Roche Applied Science, Indianapolis, IN, USA) was used for transfections.
DNA fragmentation analysis
A flow cytometric analysis was performed using a FACScan (BD Biosciences). The data analysis was performed using the Cell-Fit software program (BD Biosciences). Cell-Fit receives data from the flow cytometer and provides real-time statistical analysis, computed at 1-s intervals, and also discriminates doublets or adjacent particles. Cells with sub-G 0 -G 1 DNA contents after staining with propidium iodide were counted as apoptotic cells. In brief, after treatments, the cells were harvested and then fixed in 70% cold ethanol. Afterward, cells were stained with 0.1 mg/ml propidium iodide containing 1.5 mg/ml RNase. DNA contents of cells were then tested using a FACScan machine by Becton Dickinson (San Jose, CA, USA).
Annexin V-FITC apoptosis detection assay After treatments, cells were prepared and stained with Annexin V-FITC apoptosis detection Kit I (BD Biosciences) according to the manufacturer's instructions. Subsequently, the samples were analysed using a flow cytometer.
Immunoblot and Ras activation analyses
Cell lysates were separated using sodium dodecyl sulfatepolyacrylamide gel electrophoresis gel and transferred to nitrocellulose. After blocking with 5% non-fat milk for 1 h at room temperature, the nitrocellulose was probed with antibodies and then visualized using chemilluminescence (Perkin-Elmer, Waltham, MA, USA).
Active Ras Pull-Down and Detection kit (Thermo Scientific) was used. GTP-bound Ras was then revealed using immunoblotting. Positive control was generated by treating lysate extracted from NIH3T3 cells with GTPgS to activate Ras.
Immunoprecipitation
After treatments, extracts were pre-cleared with unrelated antibodies from the same species and then incubated with anti-PKC-d or p73 antibody, followed by incubating with the protein A/G beads (Santa Cruz Biotechnology). Immunoprecipitates were washed thrice with washing buffer (0.1% NP-40, 50 mM Tris-Cl, pH7.6, 150 mM sodium chloride, 0.1% sodium dodecyl sulfate, 1 mM dithiothreitol, 10 mM sodium fluoride, 1 mM phenylmethylsulphonyl fluoride and 1 mM NaV 3 O 4 , 10 mM b-glycerophosphate) and then eluted in sample buffer (50 mM Tris-Cl, pH 6.8, 2% sodium dodecyl sulfate, 6% 2-mercaptoethanol, 0.01% bromophenol blue and 10% glycerol) for immunoblotting analysis.
Subcellular fractions preparation
For whole cell lysates, cells were lysed with 1% NP-40 lysis buffer (1% NP-40, 50 mM Tris-Cl, pH7.6, 150 mM sodium chloride, 1 mM dithiothreitol, 10 mm sodium fluoride, 1 mM phenylmethylsulphonyl fluoride and 1 mM NaV 3 O 4 ) supplemented with protease inhibitor cocktail (Sigma-Aldrich) on ice for 30 min. After centrifugation, supernatants were collected as cell lysates. The nuclear and cytosol fractions were isolated using the nuclear/cytosol fractionation kit from BioVision (BioVision, Mountain View, CA, USA), or by following procedure. In brief, cells were incubated with 1% Triton X-114 lysis buffer (1% Triton X-114, 25 mM Tris, pH7.5, 20 mM MgCl 2 , 150 mM sodium chloride, 1 mg/ml aprotinin and 1 mg/ml leupeptin) on ice for 30 min and then homogenized by passing through a 25-gauge needle for 45 passages. After centrifuging at 280 g for 15 min, supernantant was collected as the cytosol fraction. The precipitated nuclei were then lysed with nuclear lysis buffer (50 mM Tris-Cl, pH7.6, 10 mM EDTA, 1% sodium dodecyl sulfate, 1 mM phenylmethylsulphonyl fluoride, 1 mg/ml aprotinin and 1 mg/ml leupeptin) on ice for 10 min. The nuclear extract was collected by re-centrifuging at 280 g for 15 min.
Immunofluorescence
After treatments, cells seeded on coverglass were fixed with 3.7% paraformaldehyde in 1 Â phosphate buffered saline for 10 min. After permeabilization with 0.2% Triton X-100 for 5 min at room temperature, cells were incubated with anti-PKC-d primary antibody and then incubated with an FITC-conjugated anti-rabbit secondary antibody (Invitrogen) as well as with 4 0 ,6-diamidino-2-phenylindole. The cells were visualized using Zeiss Axio Imager Z microscope (Carl Zeiss MicroImaging, Thornwood, NY, USA). The images were captured using the AxioVision Rel. 4.6 software (Carl Zeiss MicroImaging).
In vitro protein kinase C (PKC) activity assay A PKC activity assay kit (Millipore) was used. In brief, PKC-d was isolated with the antibody and incubated with PKC substrate peptide, [g-32 P]ATP, PKA/calcium/calmodulindependent kinase inhibitors as well as PKC lipid activator for 10 min at 30 1C. The 32 P-incorporated substrates were then bound to P81 filter paper, washed and quantitated using a scintillation counter.
